Myriad (MYGN) Reports Q4 Earnings: Analysis of Key Metrics

Myriad Genetics (MYGN) recently announced its financial results for the quarter ending December 2024. The company reported revenue of $210.6 million, marking a 7.1% increase compared to the same quarter last year. However, earnings per share (EPS) came in at $0.03, a slight decrease from $0.04 a year prior.

This revenue figure was marginally above the Zacks Consensus Estimate, which anticipated revenue of $210.14 million, reflecting a positive surprise of +0.22%. As for EPS, the consensus estimate was also $0.03, indicating that Myriad did not deliver an earnings surprise despite meeting expectations.

Investors are often keen to look at how revenue and earnings change year-over-year, along with any comparisons to Wall Street forecasts, to strategize their next steps. To gain clearer insights into a company's financial stability, it's essential to examine key performance metrics that significantly influence both top- and bottom-line results.

Evaluating these metrics against both past performance and analyst predictions allows investors to better gauge the potential future movement of a stock's price. Here's an overview of Myriad's performance regarding the key metrics that analysts monitored in the recently reported quarter:

• Test Volumes: 374,000 tests conducted, versus an average estimate of 384,314 from two analysts.
• Revenue by Product - Hereditary Cancer: $94.30 million, exceeding the estimated $92.29 million from three analysts, representing a year-over-year growth of +6.1%.
• Revenue by Product - Pharmacogenomics: $40.60 million compared to the expected $42.58 million, with a notable year-over-year increase of +14%.
• Revenue by Product - Tumor Profiling: $30.80 million, lower than the $33.93 million average estimate from three analysts, indicating a year-over-year decline of -4.1%.
• Revenue by Product - Prenatal: $44.90 million, slightly above the $44.75 million forecast from three analysts, showing a +12.3% improvement year-over-year.

Over the past month, Myriad's shares have experienced a return of +10.6%, contrasting with a -0.5% change in the Zacks S&P 500 composite index. Currently, the stock holds a Zacks Rank #4 (Sell), suggesting that it may underperform the broader market in the short term.

Myriad, Earnings, Analysis